Lilly acquired the Bothel, Wash., maker of the Cialis erectile dysfunction drug for $2.3 billion in December.
The massive job loss continues to be viewed as a severe blow to the region's unsuccessful struggle to grow a hometown giant to compete with such biotech hotspots as Boston and San Francisco, according to The Seattle Times.
A few companies have been started by Icos refugees. One, Cisthera, founded by a former scientist, will focus on inflammatory diseases, cancer and fibrotic diseases.
But most workers have shifted to other local companies or abandoned the area.
The CEO of a company that hired seven Icos workers, ZymoGenetics Inc., Bruce Carter, decried the impact.
"For the biotech industry in Seattle, it's a very bad thing-it's an industry where the bigger it gets, the bigger it gets," Carter said.